This segment focused on the research, development, and commercialization of small molecule and biologic therapies for inflammatory and fibrotic diseases. Research and development activities included the discovery and preclinical development of novel drug candidates, followed by clinical trials to evaluate safety and efficacy. Key technologies employed included small molecule drug design and development, as well as biologics development. The primary therapeutic areas addressed were chronic graft-versus-host disease (cGVHD) and fibrotic diseases. The lead product candidate, KD025 (belumosudil), a selective ROCK2 inhibitor, was in Phase 2 clinical trials for cGVHD. The goal was to improve patient outcomes by providing effective treatments for diseases with significant unmet medical needs. Market positioning involved targeting specific patient populations and establishing strategic partnerships. The acquisition by Sanofi in 2021 marked a significant shift in the company's strategic direction.

This segment focused on the development of KD033, an anti-PD-L1/IL-15 fusion protein, for the treatment of cancer. Research and development activities included preclinical studies and clinical trials to evaluate the safety and efficacy of KD033 in various cancer types. The technology platform involved the use of fusion proteins to enhance the immune response against cancer cells. The therapeutic area covered was oncology, with the aim of providing innovative cancer treatments. The patient impact aimed to improve survival rates and quality of life for cancer patients. Market positioning involved targeting specific cancer indications and potentially establishing partnerships for commercialization. The segment's future opportunities included expanding the clinical development of KD033 and exploring combination therapies.